EMA recommends suspension of 17-OHPC medicines in the EU

In some EU countries, 17-OHPC medicines have been authorized as injections for preventing pregnancy loss or premature birth. Credit: Victoria Moloman / Shutterstock.com. The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has advised the suspension of marketing authorizations for therapeutics containing 17-hydroxyprogesterone caproate (17-OHPC) in the European Union (EU). The recommendation follows a […]

7 mins read